<DOC>
	<DOCNO>NCT01056510</DOCNO>
	<brief_summary>This randomize , open-label , parallel group study ass effect response rate safety MabThera add either bendamustine chlorambucil patient chronic lymphocytic leukemia . Patients randomize receive six 4-week cycle either A ) MabThera ( 375mg/m2 iv day 1 cycle 1 , 500mg/m2 iv cycle 2-6 ) plus bendamustine ( 90mg/m2 first-line 70mg/m2 second-line therapy , iv day 1 2 , cycle 1-6 ) , B ) MabThera plus chlorambucil ( 10mg/m2 po daily , day 1-7 , cycle 1-6 ) . Patients group B receive 6 cycle chlorambucil monotherapy . Anticipated time study treatment 6-12 month , target sample size 600-700 individual .</brief_summary>
	<brief_title>A Study MabThera Added Bendamustine Chlorambucil Patients With Chronic Lymphocytic Leukemia ( MaBLe )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; /=18 year age chronic lymphocytic leukemia active CLL progressive Binet stage B C ineligible treatment fludarabine second line patient , pretreatment rituximab and/or chlorambucil allow EOCG performance status &gt; /=2 patient relapse within &lt; 12 month first dose prior rituximab chlorambucil firstline therapy previous plan stem cell transplantation radioimmunotherapy within 6 month prior start study treatment transformation aggressive Bcell malignancy concurrent anticancer therapy , glucocorticoid &gt; /=20mg daily prednisolone equivalent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>